Collplant Holdings (CPT) Q4 2024 Earnings Report

Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.

During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.